Vivos (RDGL) FCF Margin (2010 - 2025)

Vivos (RDGL) posted FCF Margin of 2179.84% for Q4 2025, up 91.07% sequentially from 24400.27% in Q3 2025, and up 724783.0% YoY from N/an in Q4 2024.

Vivos (RDGL) FCF Margin (2010 - 2025) Analysis & Trends

Vivos has reported FCF Margin for 15 years, with the latest figure at 2179.84% in Q4 2025.

Quarterly FCF Margin rose 724783.0% year-over-year to 2179.84% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 3009.32% (up 300618.0% YoY) and the FY2025 annual result came in at 3160.22%, up 285528.0% from the prior year.
FCF Margin rose to 2179.84% in Q4 2025 per RDGL's latest filing, from 24400.27% in the prior quarter.
Over five years, FCF Margin peaked at 1196.2% in Q3 2021 and troughed at 24400.27% in Q3 2025.
A 5-year average of 5604.82% and a median of 4182.04% in 2022 frame the typical range for FCF Margin.
The widest YoY moves for FCF Margin: up 724783 bps in 2025, down 1427513 bps in 2025.
Over 5 years, FCF Margin stood at 1196.2% in 2021, then tumbled by 262 bps to 4334.01% in 2022, then advanced by 27 bps to 3170.33% in 2023, then slumped by 197 bps to 9427.67% in 2024, then surged by 77 bps to 2179.84% in 2025.
According to Business Quant data, FCF Margin over the past three periods registered 2179.84%, 24400.27%, and 4030.07% for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Abbott Laboratories	199.12 Bn	193.52 Bn	7.27 Bn	15.81%
2	Stryker	128.79 Bn	125.32 Bn	4.50 Bn	16.07%
3	Medtronic	119.30 Bn	110.08 Bn	6.41 Bn	21.26%
4	Boston Scientific	73.50 Bn	72.96 Bn	3.85 Bn	23.50%
5	Edwards Lifesciences	52.11 Bn	47.86 Bn	1.35 Bn	33.60%
6	Dexcom	34.62 Bn	32.67 Bn	830.00 Mn	14.10%
7	GE HealthCare Technologies	34.05 Bn	31.94 Bn	2.18 Bn	1.28%
8	Koninklijke Philips	26.42 Bn	23.10 Bn	4.55 Bn	5.32%
9	Steris	23.15 Bn	22.67 Bn	684.20 Mn	18.73%
10	Vivos	24.90 Mn	23.34 Mn	-3,105.00	-2,179.84%

Download Data